Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_3

25%

Ph early_phase_1

25%

Ph not_applicable

25%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 3Large-scale testing

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(2)

Detailed Status

Withdrawn1

Terminated1

Completed1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (25.0%)

Phase 31 (25.0%)

Phase 41 (25.0%)

N/A1 (25.0%)

Trials by Status

withdrawn125%

terminated125%

completed125%

recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

completednot_applicable

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

NCT07479108

recruitingearly_phase_1

Clinical Trials (4)

Showing 4 of 4 trials

NCT07479108Not Applicable

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

Completed

NCT07055282Early Phase 1

SGLT2i in Kidney Stones

Recruiting

NCT05036317Phase 3

Empagliflozin for the Treatment of Postprandial Hypoglycemia

Terminated

NCT03437330Phase 4

Empagliflozin Effect on Glucose Toxicity

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4